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A B S T R A C T   
Adrenocortical carcinomas (ACCs) overexpress insulin-like growth factor 2 (IGF2), that drives a proliferative 
autocrine loop by binding to IGF1R and IR, but IGF1R/IR-targeted therapies failed in ACC patients. 
The cytoskeleton actin-binding protein filamin A (FLNA) impairs IR signalling in melanoma cells. 
Aims of this study were to test FLNA involvement in regulating IGF1R and IR responsiveness to both IGF2 and 
inhibitors in ACC. 
In ACC cells H295R and SW13 and primary cultures (1ACC, 4 adenomas) we found that IGF1R and IR 
interacted with FLNA, and FLNA silencing increased IGF1R and reduced IR expression, with a downstream effect 
of increased cell proliferation and ERK phosphorylation. 
In addition, FLNA knockdown potentiated antiproliferative effects of IGF1R/IR inhibitor Linsitinib and IGF1R 
inhibitor NVP-ADW742 in H295R. 
Finally, Western blot showed lower FLNA expression in ACCs (n = 10) than in ACAs (n = 10) and an inverse 
correlation of FLNA/IGF1R ratio with ERK phosphorylation in ACCs only. 
In conclusion, we demonstrated that low FLNA levels enhance both IGF2 proliferative effects and IGF1R/IR 
inhibitors efficacy in ACC cells, suggesting FLNA as a new factor influencing tumor clinical behavior and the 
response to the therapy with IGF1R/IR-targeted drugs.   
1. Introduction 
Adrenocortical carcinoma (ACC) is a rare endocrine tumor, devel-
oping from the adrenal cortex, with an incidence of 0.7–2 cases per 
million each year [1–3]. The prognosis is generally poor, with a 5-year 
overall survival of about 35% in most series and less than 20% in met-
astatic disease [4–6]. Complete surgical resection represents the only 
curative treatment for ACC, but recurrences are frequent. Inoperable or 
metastatic disease may benefit from systemic treatment with the adre-
nolytic agent mitotane, the only ACC-specific drug approved by the 
European Medicines Agency and the US Food and Drug Administration, 
but its efficacy is limited, highlighting the need for improved therapeutic 
strategies [3]. 
The pathogenesis of ACC is still poorly understood. In the last de-
cades the involvement of different genes and pathways in the tumori-
genesis and progression of ACCs has been highlighted. Among these 
emerged the role of β-catenin and Wnt signaling [7,8]. Moreover, one of 
the most frequent molecular change of ACC, observed in 80–90% of 
cases, is the overexpression of insulin-like growth factor 2 (IGF2), 
compared to normal adrenals and adrenocortical adenomas (ACAs) 
[9–17]. IGF2 promotes tumor growth in an autocrine loop by binding 
the receptor tyrosine kinase insulin-like growth factor 1 receptor 
(IGF1R) [18,19]. Moreover, IGF2 could interact with insulin receptor 
isoform A (IRA), expressed by ACC cells [20,21]. The binding of IGF2 to 
the receptors activates MAPK and PI3K/AKT/mTOR pathways, that 
culminate in increased cell proliferation, migration and protection from 
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apoptosis [22]. 
IGF2/IGF1R pathway overactivation in ACC was the rationale for 
studies testing the efficacy of pharmacological inhibitors of IGF1R, with 
promising results in preclinical in vitro and in vivo studies [15,16]. 
However, in a phase III trial a small molecule inhibitor of IGF1R and IR, 
Linsitinib (OSI-906), did not show an increased overall survival 
compared to placebo [23]. Anyway, few patients exhibited clinically 
relevant responses, including disease stabilization, tumor shrinkage, and 
long-term ACC regression [23], suggesting the urgent need for new 
biomarkers predicting the tumor responsiveness to this molecule, as well 
as for a better knowledge of the molecular mechanisms that govern 
IGF1R activity. 
The cytoskeleton protein filamin A (FLNA) is crucial in the regulation 
of intracellular trafficking, expression and signal transduction of a 
number of membrane receptors and it plays a role in regulating clinical 
behavior of other endocrine [24,25] and non-endocrine tumors 
(reviewed in [26]). FLNA is a large actin binding protein able to 
homodimerize, composed of an N-terminal actin-binding domain and 24 
Ig-like repeats of about 96 amino acids [27]. Interestingly, in melanoma 
cells FLNA directly bound to IR and impaired its ability to activate 
MAPKs [28]. The observation that loss of FLNA in mouse neural pro-
genitor cells resulted in enhanced IGF1R signalling [29] likewise sug-
gests a possible FLNA role in attenuating IGF1R signaling, but their 
interaction has yet to be proven. 
In the present study we tested in ACC cell lines and primary cultured 
cells FLNA role in regulating IGF1R and IR expression and signaling, and 
in influencing the responsiveness to IGF1R/IR inhibitors. Moreover, we 
tested FLNA expression in human ACC tissues by Western blot analysis. 
Our results identify FLNA as a repressor of IGF2 signalling and recognize 
the loss of FLNA as a potential biomarker for ACC responsiveness to anti 
IGF1R/IR therapy. 
2. Materials and methods 
2.1. Cell cultures and adrenal tissues 
Human adrenocortical carcinoma H295R cells (Cat# CRL-2128, 
RRID: CVCL_0458, ATCC) and SW13 cells (Cat# CCL-105, RRID: 
CVCL_0542, ATCC) were obtained from American Type Culture 
Collection. SW13 cells were tested and authenticated by genetic 
profiling using polymorphic short tandem repeat (STR) loci with Pow-
erPlex Fusion system (Promega, BMR Genomics Cell Profile service, 
Italy) that allows to amplify 23 loci STR (D3S1358, D1S1656, D2S441, 
D10S1248, D13S317, Penta E, D16S539, D18S51, D2S1338, CSF1PO, 
Penta D, TH01, vWA, D21S11, D7S820, D5S818, TPOX, DYS391, 
D8S1179, D12S391, D19S433, FGA, D22S1045) and Amelogenin locus 
for gender determination. Results were compared to reference cell line 
databases (ATCC, DSMZ, JCRB and RIKEN) and the best matches were 
found. The analysis was carried out on May 17, 2018 and cells were 
subsequently used for less than 6 months for experiments. H295R cells 
were used for fewer than 6 months after receipt. For both cell lines the 
maximum passage number used for experimentation was 20. H295R 
cells were grown in DMEM:F12 1:1 (Cat# 11320033, Gibco, Invitrogen, 
Life Technologies Inc, Carlsband, CA, USA) supplemented with 1% ITS 
+ Premix (Cat# 355100, Corning, NY, USA), 2.5% Nu-Serum I (Cat# 
354352, Corning, NY, USA), 2 mM glutamine and 100 U/ml penicillin, 
and 100 μg/ml streptomycin (Cat# 17-602E, Lonza group Ltd, Basel, 
Swi). SW13 cells were cultured in DMEM:F12 1:1, supplemented with 
10% fetal bovine serum (FBS) (Cat# 16000044, Gibco, Invitrogen, Life 
Technologies Inc, Carlsband, CA, USA), 2 mM glutamine, 100 U/ml 
penicillin and 100 μg/ml streptomycin. 
The human M2 melanoma cell line and the stable subclone, A7, were 
kindly gifted by Prof. Nakamura (Brigham and Women’s Hospital, 
Boston, MA). Both cell lines were cultured in MEM (Cat# M4655, Sigma 
Aldrich, St. Louis, MO) supplemented with 8% Newborn Calf serum 
(Cat# 16010159, Gibco, Invitrogen, Life Technologies Inc, Carlsband, 
CA, USA), 2% FBS, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml 
streptomycin. The A7 cells were grown with the addition of G418 
disulfate salt 200 μg/ml (Cat# A1720, Sigma Aldrich, St. Louis, MO) to 
maintain FLNA expression. 
Fresh tissues (ACC, n = 1, ACAs, n = 4) were used to obtain primary 
cell cultures whereas frozen tissue samples (ACCs, n = 10, ACAs, n = 10) 
were subjected to protein extraction and subsequently analysed by 
Western blot. The study was approved by the local ethics committee and 
each patient gave informed consent to the use of his/her tumor sample 
and clinical information. 
Briefly, fresh tissues were subjected to mechanical and enzymatic 
digestion using a solution of 2 mg/mL collagenase (Cat# C9891, Sigma 
Aldrich, St. Louis, MO) dissolved in DMEM (Cat# AL007A, Sigma 
Aldrich, St. Louis, MO) at 37 ◦C for 2 h. In order to remove undigested 
material, the digested tissue was passed on a 100-μm filter (nylon cell 
strainer, BD Transduction Laboratories, Lexington, UK) and the obtained 
cell suspension was centrifuged (1000 rpm, 10 min). After this centri-
fugation step, cells were pelleted at the bottom of the tube, while adi-
pocytes were found on the surface as a ring due to their low density. At 
this step, the adipocyte ring was transferred to a new tube and discarded. 
Pelleted cells were cultured in DMEM supplemented with 20% FBS, 2 
mM glutamine and 100 U/ml penicillin, and 100 μg/ml streptomycin. 
Frozen tissues were subjected to mechanical dissection with the use 
of a scalpel, lysed in 100 μl of lysis buffer (Cat# 9803S, Cell signalling 
technology, Danvers, MA), with the addition of protease inhibitors 
(Roche, Monza, IT) for 10 min on ice, then centrifuged at 1200 rpm, 10 
min at 4 ◦C. The supernatant containing extracted proteins was collected 
in fresh tube. Proteins were quantified by BCA assay. 
2.2. Coimmunoprecipitation assay 
Immunoprecipitation was performed as previously described [30]. 
To avoid interference of growth factors present in cell culture media, the 
experiments were performed in the absence of serum, and supplemental 
factors (ITS + premix), thus in DMEM:F12 1:1. Cells were then stimu-
lated or not with IGF2 100 ng/ml (Cat# 100–12, Peprotech, Rocky Hill, 
NJ, USA). Briefly, 100 μg of total protein extracted from cells were 
incubated on a rotating device with 4 μg FLNA antibody (Cat# 
H00002316-M01, RRID:AB_425437; Abnova Corporation, Tapei City, 
Taiwan) for 16 h at 4 ◦C and then with 20 μl of protein A/G Plus-Agarose 
for 3 h at 4 ◦C (Cat# sc-2002, Santa Cruz Pharmaceutical Inc, Santa 
Cruz, CA). Mouse IgG1 isotype control (Cat# MA1-10404, RRID: 
AB_2536772; Thermo Fisher Scientific, Rockford, IL) was used as 
negative control to measure the non-specific binding. Eluted proteins 
were resolved by SDS-PAGE and transferred to a nitrocellulose filter. 
Immunoblotting was performed with anti-FLNA antibody (1:1000 
dilution), anti-IGF1R (Cat# 28897, RRID:AB_2798965, Cell Signaling 
Technology, Danvers, MA; 1:1000 dilution) and anti-IR antibodies (Cat# 
3025, RRID:AB_2280448, Cell Signaling Technology, Danvers, MA; 
1:1000 dilution). 
For IGF1R and IR immunoprecipitation, 400 μg of total protein 
extracted from cells were incubated on a rotating device with IGF1R 
antibody (dilution 1:100) or IR antibody (dilution 1:50). 
2.3. In situ proximity ligation assay (PLA) 
PLA experiments were performed using reagents and instructions 
provided by a commercially available kit (Duolink In Situ Detection 
Reagents Red) from Sigma-Aldrich (St Louis, MI, USA). H295R were 
plated at the density of 1.5 × 105 cells/well and SW13 at 2 × 104 cells/ 
well on 13-mm poly-L-lysine (Cat# P4707, Sigma-Aldrich, St Louis, MI, 
USA) coated coverslips in 24-well plates. Both were cultured in a starved 
culture medium and free of ITS + Premix for H295R, and stimulated or 
not with IGF2 100 ng/ml. 
Cells were fixed for 10 min at room temperature with 4% para-
formaldehyde (Cat# P6148, Sigma-Aldrich, St. Louis, MO), followed by 
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three washes with PBS and incubated 1 h at room temperature with 
blocking buffer (5% FBS, 0.3% Triton™X-100, in PBS). The overnight 
incubation with anti-FLNA (1:200) and anti-IGF1R (1:100) or anti-IR 
(1:50) antibodies was performed at 4 ◦C. The following day, second-
ary probes anti-mouse and anti-rabbit attached to oligonucleotides were 
added and, after washing, the oligonucleotides of the bound probes 
where ligated and then amplified. Finally, slides were mounted with 
Duolink Mounting Medium with 4′,6 diamidino-2-phenylindole (DAPI) 
on glass slides and analysed by fluorescence microscopy (Axio Vert.A1, 
Zeiss). PLA probe incubation time and rolling circle amplification times 
were all optimized for this specific application. Technical negative 
control slides were prepared with omission of each primary antibody 
separately and omission of all primary antibodies. Proximity ligation 
events were quantified with NIH ImageJ software after image decon-
volution in agreement with previously published approaches [31]. 
2.4. FLNA and IGF1R silencing 
Small interfering RNAs (siRNAs) against human FLNA and IGF1R 
gene were purchased from Dharmacon (Cat# FE5L003012000005, 
Smart pool siRNAs, Dharmacon, GE Healthcare Life Sciences, Chicago, 
IL, USA). Subconfluent H295R cells were transfected with FLNA siRNAs 
using Viromer Blue for miRNA/siRNA transfection reagent (Cat# VB- 
01LB-01, Lipocalyx GmbH, Halle, D) and SW13 cells with Dharmafect 
transfection agent 2 (Cat# T-2002-03, Dharmacon, GE Healthcare Life 
Sciences, Chicago, IL), according to manufacturer’s instructions. Pre-
liminary experiments aimed to determine the optimal concentration of 
siRNAs and the kinetics of silencing of FLNA and IGF1R alone and 
together were performed. In each experiment a negative control siRNA, 
a non-targeting sequence without significant homology to the sequence 
of human, mouse or rat transcripts was used. Western blotting was 
performed in each experiment to control the expression level of FLNA, 
IGF1R and FLNA + IGF1R in silenced cells with 1:1000 dilution of anti- 
FLNA antibody and anti-IGF1R. The membranes were stripped and 
reprobed with an anti-GAPDH antibody (Cat# AM4300, RRID: 
AB_437392; Ambion, Life Technologies Inc, Carlsband, CA, 1:4000 
dilution). Only experiments with silencing efficiency >80% were 
accepted. Experiments were repeated at least 3 times. 
2.5. FLNA transfection 
Transient transfections of the plasmid encoding FLNA (pREP 4 fila-
min A expression vector) [30] were performed using Lipofectamine 
2000 transfection reagent (Invitrogen) according to the manufacturer’s 
instruction. An empty vector was used in each experiment as negative 
control. Western blot analysis was performed in each experiment to 
control the expression level of FLNA in transiently transfected cells. 
Experiments were repeated at least 3 times. 
2.6. Western blot analysis 
Total proteins extracted from cultured cells were quantified by BCA 
assay, separated on SDS/polyacrylamide gels and transferred to a 
nitrocellulose filter. Anti-IGF1R, anti-IR, anti-Cyclin E1 (Cat# 4129, Cell 
Signaling Technology, Danvers, MA), anti-Caspase-3 (Cat# 9662, Cell 
Signaling Technology, Danvers, MA), phospho and total p44/p42 MAPK 
ERK1/2 (Cat# MAB-91982 and Cat# AB-82379, respectively, Immu-
nological Sciences, Rome, Italy), total AKT (Cat# MAB-94324, Immu-
nological Sciences, Rome, Italy), were used at 1:1000. Phospho-AKT 
(Ser473) antibody was used at 1:2000 (Cat# ABP-0637, Immunological 
Sciences, Rome, Italy) and IGF2 antibody (Cat# ab9574, Abcam, Cam-
bridge, UK) was used 0.2 μg/ml. The detection of phosphorylated pro-
teins was normalized on total proteins. GAPDH was used as 
housekeeping. Chemiluminescence was detected using the Chemidoc-IT 
Imaging System (UVP, Upland, CA) and densitometrical analysis was 
performed with NIH ImageJ software. Experiments were repeated at 
least 3 times. 
2.7. Cell proliferation assay 
Cell proliferation was assessed by colorimetric measurement of 5- 
bromo-2-deoxyuridine (BrdU) incorporation during DNA synthesis in 
proliferating cells as previously reported [32], according to the in-
struction of the manufacture (GE Healthcare, Life Science, Buck-
inghamshire, UK). Cells were plated in a 6-well plate at the density of 3 
× 105 for H295R, 1 × 105 for SW13 and 2.5 × 105 for ACA primary 
cultured cells (n = 4) and after FLNA silencing of 72 h were transferred 
in a p96 multiwell at a density of 1.7 × 104. After that, cells were treated 
or not with: Linsitinib (Cat# S1091, Selleck Chemicals, Houston, TX, 
USA) or NVP-ADW742 (Cat# SML1921, Sigma Aldrich, St. Louis, MO) at 
indicated concentration or only with IGF2 100 ng/ml for 24 h. SW13 
cells after incubation with IGF1R or IGF1R/IR inhibitor were also 
treated with IGF2 100 ng/ml for additional 24 h. BrdU was added to 
H295R and SW13 for 2 h and to ACAs for 24 h at 37 ◦C. All experiments 
were repeated at least 3 times and each determination was done in 
triplicate. 
2.8. Apoptosis assay 
Caspase-3/7 enzymatic activity was measured using Apo-ONE Ho-
mogeneous Caspase-3/7 Assay (Promega, WI, USA) according to the 
instruction of the manufacturer. Silenced cells were seeded at a density 
of 1.7 × 104 cells/well in a 96-well plate. The amount of fluorescent 
product generated from a profluorescent caspase-3/7 consensus sub-
strate is representative of the amount of active caspase-3/7 present in 
the sample. Experiments were repeated 3 times and each determination 
was done in quintuple. 
2.9. Statistical analysis 
The results are expressed at the mean ± S.D. A paired two-tailed 
Student’s t-test was used to assess the significance between two series 
of data. ACAs vs ACCs densitometric data were analysed by the non- 
parametric Pearson chi-squared test. Spearman’s correlation coeffi-
cient was used to show direct correlations. Calculations were performed 
by GraphPad Prism 7.0 software (GraphPad Software, Inc, La Jolla, CA). 
p < 0.05 was accepted as statistically significant. 
3. Results 
3.1. In ACC cell lines FLNA interacts with IGF1R and IR 
We used two human cell lines, the ACC cell line H295R, and SW13 
cells, a model useful to test the absence of IGF2, although of uncertain 
adrenocortical derivation. According to published data [16,33–35], we 
found that only H295R express IGF2 protein (data not shown), and that 
both cell lines express IGF1R, IR and FLNA at comparable levels (Suppl. 
Fig. 1A–C). 
It has been shown that FLNA interacts directly with IR in glutathione 
S-transferase (GST) pull-down assays and immunoprecipitation assays in 
A7 melanoma cells [28], while no data are available demonstrating 
FLNA-IGF1R interaction. 
Here, we used two different techniques to analyze the interaction 
between IGF1R-FLNA and IR-FLNA both in the presence and absence of 
IGF2. 
Immunoprecipitation assays of FLNA in H295R cells showed that 
FLNA was able to coimmunoprecipitate IGF1R in basal conditions 
(Fig. 1A). Moreover, 10 min stimulation with IGF2 100 ng/ml increased 
the recruitment of FLNA to the receptor (1.7 ± 0.1-fold vs basal, p <
0.001), that remains stable at 30 min of incubation with IGF2. Since 
H295R cells, but not SW13 cells, express and secrete in culture medium 
large amounts of IGF2 [16,34,35], to test the interaction IGF1R-FLNA in 
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the absence of IGF2 we used SW13 cells. Our results showed the pres-
ence of IGF1R in the immunoprecipitates also in basal condition 
(Fig. 1B), suggesting a constitutive interaction between IGF1R and 
FLNA. As observed in H295R, FLNA recruitment to IGF1R increased 
after IGF2 stimulation (1.8 ± 0.3-fold at 30 min vs basal, p < 0.001). 
In both ACC cell lines, FLNA was able to coimmunoprecipitate IR in 
basal conditions. IR interaction with FLNA was transient and decreased 
after stimulation with IGF2 (− 35.7 ± 20.2% and − 46.7 ± 22.6% after 
10 min IGF2 incubation in H295R and SW13, respectively, p < 0.05) 
(Fig. 1C&D). 
The interaction of FLNA with IGF1R and IR in H295R and SW13 cells 
was confirmed by immunoprecipitating the receptors and blotting for 
FLNA (Suppl. Fig.2). 
We then performed in situ proximity ligation assay (PLA) between 
FLNA and IGF1R or IR in H295R and SW13 cells. Consistently, the 
presence of PLA signals (green dots) indicate a close proximity (at dis-
tances < 40 nm) between IGF1R and FLNA (Fig. 1E) and IR and FLNA 
(Fig. 1F) in both cell lines. Furthermore, the quantification analysis of 
PLA signals confirmed a significantly enhancement of IGF1R-FLNA 
interaction (120.7 ± 3.4%, p < 0.05 and 149.6 ± 4.78%, p < 0.001 in 
H295R and SW13, respectively, Fig. 1E) and a reduction of IR-FLNA 
(− 16.6 ± 4.4%, p < 0.05 and − 25.6 ± 2.85%, p < 0.01 in H295R and 
SW13, respectively, Fig. 1F) after 10 min of incubation with IGF2. 
3.2. FLNA silencing increases IGF1R and decreases IR expression 
To test the effects of FLNA on IGF1R and IR expression, we silenced 
cells with siRNAs specific for FLNA. 
In H295R cells, IGF1R expression levels were significantly increased 
in FLNA silenced cells with respect to cells transfected with negative 
control siRNAs (1.4 ± 0.2-fold, p < 0.01). In SW13 cells, that do not 
secrete IGF2, in contrast to H295R, FLNA knockdown did not alter 
IGF1R in basal condition, but strongly increased IGF1R expression upon 
24 h IGF2 incubation (2.3 ± 0.8-fold vs IGF2 stimulated control cells, p 
< 0.05) (Fig. 2A&B). 
In contrast, FLNA silencing reduced IR expression, both in H295R 
cells (− 85.5 ± 9.1%, p < 0.001) and in SW13 cells after IGF2 stimulation 
(− 27.2 ± 18.2% vs IGF2 stimulated control cells, p < 0.05) (Fig. 2C&D). 
To replicate these experiments in ACC primary cultured cells, we 
tested 3 ACCs for FLNA expression. Only one expressed FLNA at 
detectable levels, and was used for FLNA silencing experiments. In pri-
mary cultured ACC cells, FLNA silencing increased IGF1R expression 
(2.9-fold vs control cells) but did not alter IR expression levels (Fig. 2E). 
To test a possible effect of FLNA overexpression on the amount of 
IGF1R and IR, we transiently transfected FLNA in H295R cells. We found 
that FLNA overexpression did not impact on IGF1R and IR expression 
(Fig. 2F&G). 
3.3. FLNA silencing increases IGF2 proliferative effects 
We then examined the effects of FLNA silencing on the intracellular 
responses elicited by IGF2. H295R cells proliferation was significantly 
increased (130 ± 13.4%, p < 0.01) in FLNA silenced cells compared to 
negative control cells (Fig. 3A). In SW13 cells, FLNA knockdown 
increased basal cell proliferation (131.2 ± 6.7% vs control cells, p <
0.001) and enhanced the mitogenic effects of IGF2 (144.3 ± 23.8% vs 
IGF2 stimulated control cells, p < 0.05) (Fig. 3B). 
In agreement, by measuring ERK phosphorylation, we found that 
FLNA silencing in H295R cells induced an increase of P-ERK/total ERK 
ratio (1.3 ± 0.1-fold vs control cells, p < 0.01), that was completely 
abolished in the absence of IGF1R in double-silenced cells, suggesting 
that ERK phosphorylation is increased by FLNA silencing downstream 
IGF1R signalling (Fig. 3C). 
Accordingly, we found a significant increase in cyclin E1 expression 
after FLNA silencing in H295R (1.55 ± 0.3-fold vs control cells, p < 0.05) 
(Fig. 3D). 
On the contrary, cell apoptosis was not affected by FLNA silencing, as 
demonstrated by caspase 3/7 activity assay (Fig. 3E) and by the Western 
blot analysis of pro-caspase 3 and cleaved caspase 3 (Fig. 3F), in H295R 
cells. In line with these results, we found that FLNA silencing in H295R 
cells did not change P-AKT/total AKT ratio (Fig. 3G). 
In primary ACC cells, FLNA silencing strongly increased ERK phos-
phorylation (4.3-fold vs control cells) (Fig. 3H). IGF2 as expected pro-
moted ERK phosphorylation in control cells (2.2-fold increase), but only 
slightly further increased ERK phosphorylation in FLNA silenced cells 
with respect to basal (1.14-fold). However, it should be noted that 
pERK/ERK ratio upon IGF2 incubation was 2.2-fold higher in FLNA 
silenced cells vs control cells (Fig. 3H). 
Fig. 1. Interaction of FLNA with IGF1R and 
IR. A-D) Coimmunoprecipitation assays. 
H295R and SW13 were treated for the indi-
cated times with 100 ng/ml IGF2. Lysates 
were immunoprecipitated with FLNA anti-
body and the presence of IGF1R, IR and 
FLNA in immunoprecipitates was tested by 
immunoblotting. Representative images of 
one of 3 independent experiments are 
shown. The graphs show mean ± S.D. from 3 
independent experiments, normalized vs 
basal. * = p < 0.05, *** = p < 0.001 vs 
basal. E&F) FLNA-IGF1R and FLNA-IR 
interaction tested by proximity ligation 
assay (PLA) in H295R and SW13 cells. Cells 
were incubated or not with 100 ng/ml IGF2. 
Each picture represents a typical cell stain-
ing observed in 10 fields randomly chosen. 
Positive PLA signals are visualized as green 
fluorescent spots. Nuclei are stained with 
DAPI (blue). Scale bar 10 μm. Quantification 
of total FLNA-IGF1R (E) and FLNA-IR (F) 
puncta representing PLA events are shown 
(n = 3 and ~2000 total puncta quantified 
per condition in cells randomly chosen from 
different fields, * = p < 0.05, ** = P < 0.01, 
*** = p < 0.001).   
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Fig. 2. FLNA silencing increases IGF1R and decreases IR expression. H295R (A&C), SW13 (B&D) and ACC primary cultured cells (E) were transiently transfected 
with FLNA siRNAs or negative control siRNAs (C- siRNA) for 72 h. SW13 cells were also treated or not with IGF2 100 ng/ml for 24 h. Membranes were incubated with 
FLNA, IGF1R or IR antibodies, stripped and reprobed with anti-GAPDH antibody. The graphs show densitometrical analysis of IGF1R (A&B) or IR (C&D) normalized 
to GAPDH (mean ± S.D. from 3 independent experiments). Representative immunoblots are shown. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. E) IGF1R and IR 
expression in ACC primary cultured cells silenced for FLNA. FLNA silencing induced an increase of IGF1R expression compared to control cells. F&G) IGF1R and IR 
expression in H295R transiently transfected with wild type FLNA expression vector for 48 h. Membranes were incubated with FLNA, IGF1R or IR antibodies, stripped 
and reprobed with anti-GAPDH antibody. The graphs show densitometrical analysis of IGF1R (F) or IR (G) normalized to GAPDH (mean ± S.D. from 3 independent 
experiments). Representative immunoblots are shown. 
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Fig. 3. FLNA knockdown potentiates IGF2 
effects on cell proliferation and ERK phos-
phorylation. Proliferation assays in H295R 
(A) and SW13 (B) cells silenced for FLNA. 
SW13 cells were stimulated or not with IGF2 
100 ng/ml for 24 h. BrdU was added for 2 h 
to silenced cells and its incorporation in 
newly synthesized DNA was measured. Ex-
periments were repeated at least 3 times and 
each determination was done in triplicate. 
Values represent mean (±S.D.) expressed as 
percentage of basal C- siRNA. * = p < 0.05, 
** = p < 0.01, *** = p < 0.001 C) Analysis 
of P-ERK/total ERK ratio in H295R silenced 
for FLNA, IGF1R or FLNA + IGF1R. Mem-
branes were incubated with P-ERK antibody, 
stripped and reprobed with total ERK anti-
body. Representative immunoblots and 
densitometric analysis of P-ERK normalized 
to total ERK are shown. Immunoblots of 
FLNA, IGF1R and GAPDH are presented to 
demonstrate silencing efficiency (mean ± S. 
D. from 3 independent experiments). ** = p 
< 0.01 vs control cells. D) Proteins were 
extracted from H295R silenced cells and 
cyclin E1 expression was evaluated. Repre-
sentative immunoblots and densitometric 
analysis of cyclin E1 normalized to GAPDH 
are shown (mean ± S.D. from 3 independent 
experiments). * = p < 0.05 vs control cells. 
E) FLNA knockdown does not affect cell 
apoptosis. Caspase-3/7 activity was 
measured. Data represent mean ± S.D. of 3 
independent experiments. Each determina-
tion was done in quintuplicate. F) Repre-
sentative immunoblot showing pro-caspase- 
3, cleaved-caspase-3 and relative GAPDH in 
H295R silenced for FLNA. As positive con-
trol we treated cells with okadaic acid (OA) 
1 μM for 24 h. G) Proteins were extracted 
from H295R silenced cells. Membranes were 
incubated with P-AKT (Ser473) antibody, 
stripped and reprobed with total AKT. 
Representative immunoblots and densito-
metric analysis of P-AKT normalized to total 
AKT are shown. H) P-ERK/total ERK ratio in 
ACC primary cultured cells silenced for 
FLNA incubated with or without IGF2 100 
ng/ml for 10min. The values above immu-
noblot images indicate densitometric anal-
ysis of P-ERK normalized to total ERK. I) 
Representative immunoblot and densito-
metric analysis of P-ERK/total ERK ratio in 
ACA primary cultured cells silenced for 
FLNA. Values represent mean (±S.D.) from 4 
ACAs. * = p < 0.05 vs control cells. L) Pro-
liferation assay in ACA primary cultured 
cells silenced for FLNA and stimulated with 
IGF2 100 ng/mL for 24 h. FLNA silencing 
induced an increase of cell proliferation 
compared to control cells. Values represent 
mean (±S.D.) from 4 ACAs expressed as 
percentage of basal C- siRNA. ** = p < 0.01.   
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Due to the rarity of ACC, we decided to replicate proliferation ex-
periments in ACAs. Moreover, ACAs express higher levels of FLNA than 
ACCs (see paragraph 5 of Results), being more suitable for FLNA 
silencing experiments. In agreement with ACC cells, we found that in 
primary cultured ACA cells (n = 4) FLNA silencing increased both P- 
ERK/total ERK ratio (2.68 ± 1.18-fold vs control cell, p < 0.05) (Fig. 3I 
and Suppl. Fig.3) and cell proliferation (127.6 ± 14.3% vs control cells, 
p < 0.01) (Fig. 3L). 
Western blot analysis revealed that the expression of IGF2 was 
comparable in 2 ACAs and ACC, whereas was almost undetectable in the 
other 2 ACAs (Suppl. Fig. 4). 
3.4. FLNA silencing potentiates antiproliferative effects of IGF1R 
inhibitors Linsitinib and NVP-ADW742 
We then tested the effects of FLNA silencing on the antiproliferative 
effects of IGF1R inhibitors. We used Linsitinib, a dual IGF1R/IR inhib-
itor, and NVP-ADW742, an IGF1R-selective tyrosine kinase inhibitor 
[36], to discriminate the specific role of IGF1R with respect to IR. 
In H295R cells silenced for FLNA the lowest concentration of Linsi-
tinib that had a growth-inhibitory effect after 24 h incubation was 0.1 
μM (− 9.9 ± 4% proliferation vs basal, p < 0.001), whereas no effect was 
observed in these experimental conditions in negative control cells 
(Fig. 4A). 1 μM Linsitinib reduced cell proliferation by 38.2 ± 16.6% vs 
basal (p < 0.001) in FLNA silenced cells and 22.2 ± 13.5% in negative 
control cells (p < 0.001 vs basal and p < 0.05 vs silenced cells) (Fig. 4A). 
SW13 cells were not responsive to low doses of Linsitinib (Fig. 4B). 
Interestingly, a significant reduction of cell proliferation was found at 5 
μM Linsitinib in FLNA silenced cells (− 37.3 ± 9.4% vs basal, p < 0.05), 
but not in control cells. However, this concentration is above the human 
maximal plasma concentration (3.1 μM) [23,37]. We cannot exclude 
toxic effects in cells treated with concentrations higher than 5 μM. 
In H295R, NVP-ADW742 0.5 μM induced a decrease of cells prolif-
eration in FLNA silenced cells (− 24.6 ± 13.5% vs basal, p < 0.05), and 
only a slight non significant effect in control cells. At 1 μM, it was more 
effective in silenced cells (− 46.3 ± 16.1% cell proliferation, p < 0.001 vs 
basal) than in control cells (− 26.5 ± 13.8%, p < 0.001 vs basal and p <
0.05 vs silenced cells) (Fig. 4C). Similar to what observed with Linsitinib, 
SW13 were not responsive to low concentrations of NVP-ADW742, but a 
strong reduction of cell proliferation was observed in both control cells 
and silenced cells at 5 μM and 10 μM (Fig. 4D). 
Overall, these data suggest that FLNA knockdown potentiates the 
effects of both IGF1R/IR and IR inhibitors on H295R cell proliferation. 
The decrease in cell proliferation induced by Linsitinib and NVP- 
ADW742 was associated with a slight but not significant reduction of 
ERK phosphorylation (Suppl. Fig.5), with no differences between 
silenced and control cells. 
The treatment with Linsitinib and NVP-ADW742 did not affect the 
expression of IGF1R, IR and FLNA (Suppl. Fig.6). 
Since FLNA silencing efficiency in H295R and SW13 cells reached 
about 90%, to test the effects of a complete absence of FLNA we used 
FLNA-deficient M2 and derivative rescued sub-lines A7 human mela-
noma cells, expressing FLNA [38]. These cells express IGF1R at similar 
levels in basal condition, as well as after 24 h IGF2 stimulation (Suppl. 
Fig.7A). However, we found that IGF2 was able to increase ERK phos-
phorylation in M2 (2.1 ± 0.5-fold vs basal, p < 0.05), lacking FLNA, but 
not in A7 cells, confirming the FLNA role in preventing IGF1R signaling 
(Suppl. Fig.7B). In addition, only M2 cells were responsive to Linsitinib 
inhibitory effects on ERK phosphorylation in the presence of IGF2 
(− 81.6 ± 32% vs IGF2 alone, p < 0.01) (Suppl. Fig7B). 
3.5. FLNA expression in ACCs and ACAs and correlation with the IGF 
pathway 
We analysed FLNA expression in 10 ACC and 10 ACA tissue samples 
by Western blot analysis (Fig. 5A). FLNA levels were highly variable in 
ACC tissues, but significantly lower than in ACA (mean FLNA/GAPDH 
ratio 0.37 ± 0.38 in ACC and 0.90 ± 0.63 in ACA, p < 0.05) (Fig. 5B). In 
ACC, we observed a high heterogeneity in IGF1R expression. Mean 
IGF1R expression was comparable between ACCs (mean IGF1R/GAPDH 
ratio 0.129 ± 0.126) and ACAs (mean IGF1R/GAPDH ratio 0.190 ±
0.185) (Fig. 5B). No significant correlation between IGF1R and FLNA 
expression has been found in ACC. Nevertheless, FLNA/IGF1R ratio and 
FLNA/IR ratio inversely correlated with P-ERK/total ERK ratio in ACCs 
(Spearman’s coefficient − 0.68 and − 0.71, respectively, p < 0.05) 
(Fig. 5C&D) but not in ACAs. This suggests that low FLNA levels, in the 
presence of high IGF1R and/or IR amount, corresponded to an 
enhancement of IGF1R pathway in ACCs. 
Fig. 4. FLNA silencing improves Linsitinib 
and NVP-ADW742 effects on cell prolifera-
tion. H295R and SW13 proliferation assays. 
Silenced cells were incubated for 24 h with 
or without Linsitinib (A&B) or NVP- 
ADW742 (C&D) at the indicated concentra-
tions. SW13 cells were also stimulated with 
IGF2 100 ng/ml for additional 24 h. BrdU 
was added for 2 h. Values represent mean 
(±S.D.) expressed as % respective basal. All 
experiments were repeated at least 3 times 
and each determination was done in tripli-
cate. * = p < 0.05, ** = p < 0.01, *** = p <
0.001 vs basal condition. §, p < 0.05 vs 
negative control.   
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4. Discussion 
The present study identified cytoskeleton protein FLNA as a 
repressor of IGF2 signalling and investigated how loss of FLNA affects 
IGF1R signalling and the response to anti-IGF1R therapies. 
The activation of the complex IGF axis, triggered by IGF2 over-
expression in ACC, promotes the autonomous growth of ACC cells. IGF2 
binds to IGF1R leading to activation of MAPKs and PI3K/AKT pathways, 
that increased cancer cell proliferation, survival and migration. 
Moreover, IGF2 binds to the isoform A of the insulin receptor (IRA), 
whose contribution to IGF2 mitogenic effects has been poorly clarified, 
and to the mannose 6-phosphate/insulin-like growth factor 2 receptor 
(IGF2R), a scavenger receptor involved in the internalization and 
degradation of IGF2. Recently, an high expression of IGF2R has been 
observed in most ACCs, suggesting that a high level of IGF2R protein 
might counteract the growth-stimulating effects of IGF2 in adrenocor-
tical tumorigenesis [20]. Despite promising results of preclinical studies 
[15,16], IGF1R/IR inhibitors failed in clinical trials in most ACC pa-
tients. To date, molecular determinants of responsiveness are unknown. 
The ACC cell line H295R is a good model to study the regulation of 
IGF system in the development of these tumors, since it presents a high 
abundance of IGF2 mRNA and protein [16,34,35]. The use of SW13 cells 
Fig. 5. FLNA expression in ACCs and in 
ACAs. A) Representative immunoblot of 
FLNA, IGF1R, IR, P-ERK, total ERK and 
GAPDH expression in 10 ACCs, 10 ACAs and 
H295R. B) The graph shows densitometric 
analysis of FLNA and IGF1R expression 
normalized to GAPDH (mean ± S.D.). * = p 
< 0.05. H295R whole cell lysates were 
included to normalize all the blots to the 
same control sample. C&D) Scatterplot rep-
resenting the inverse linear correlation be-
tween FLNA/IGF1R ratio (C) and FLNA/IR 
ratio (D) with pERK/total ERK ratio in ACCs.   
Fig. 6. Schematic representation of the FLNA impact 
on the signal transduction pathways in ACC cells. 
Left: Low/absent FLNA expression potentiates the 
effect of IGF2, IGF1R/IR inhibitor Linsitinib and 
specific IGF1R inhibitor NVP-ADW742. IGF1R medi-
ates an increase of cell proliferation, though an effi-
cient ERK phosphorylation and cyclin E1 expression, 
and a reduction of cell apoptosis through AKT phos-
phorylation. In the absence of FLNA, IR might be 
preferentially directed to a degradation pathway 
upon agonist stimulation. IGF1R inhibitors efficiently 
inhibit cell growth. Right: FLNA binds to IGF1R and 
IR, with opposite effects. FLNA might promote IGF1R 
downregulation, while protecting IR from degrada-
tion upon IGF2 binding. Furthermore, FLNA functions 
as a specific repressor of the IGF2-induced signaling 
cascade that, through ERK phosphorylation and 
cyclin E1 expression, increases cell growth, whereas 
the AKT pathway is not affected by FLNA. In the 
presence of FLNA, Linsitinib and NVP-ADW742 
display a minor impact on cell proliferation.   
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is more controversial. They are commonly used as a model for 
non-functional adrenocortical cancer, but it is unclear whether they 
derive from a primary cancer arising from the adrenal cortex or from 
metastasis to the adrenal cortex [39]. However, we decided to use this 
cell line, endogenously expressing IGF1R, but not IGF2, to test the effects 
of the absence of IGF2. Moreover, we used primary ACC cell cultures 
derived from human surgically removed ACCs and ACAs to assess FLNA 
effects in a more representative model. 
First, we demonstrated that FLNA interacts with both IGF1R and IR 
in H295R and SW13 cells by in situ proximity ligation assay, a method 
that allows to detect the close proximity of two proteins in intact fixed 
cells. 
IGF2 stimulation induced opposite effects on FLNA binding for 
IGF1R and IR, increasing IGF1R-FLNA interaction, while reducing IR- 
FLNA binding. Subsequent experiments testing IGF1R and IR expres-
sion revealed that the presence of FLNA is able to differentially regulate 
receptors expression upon IGF2 stimulation. In the presence of IGF2, 
that is produced and secreted in culture medium by H295R and primary 
cells, and exogenously added to SW13 cells, genetic silencing of FLNA 
induced an increase of IGF1R expression levels in both ACC cell lines and 
primary cultured cells. In contrast, IR was reduced (in cell lines) or 
unchanged (in primary cells) after FLNA silencing. Nevertheless, FLNA 
transfection did not impact on IGF1R and IR expression, a result in line 
with previous observation on scaffold proteins, whose overexpression 
might induce a dilution of the partner molecules [40]. 
Further experiments are required to investigate the molecular 
mechanisms underlying the FLNA effects on the expression of IGF1R and 
IR. Based on previously published data, we can hypothesize that FLNA 
might promote IGF1R downregulation, while protecting IR from 
degradation upon IGF2 binding (Fig. 6). Indeed, it is well recognized 
that FLNA is directly involved in regulating endocytosis processes, post- 
endocytic trafficking and downregulation of different membrane re-
ceptors [30,41–45]. In particular, the epidermal growth factor receptor 
(EGFR) requires FLNA for sorting into the degradation pathway in 
melanoma cells [43]. The authors demonstrated that EGFR showed 
comparable rates of EGF-mediated endocytosis in M2 (lacking FLNA) 
and A7 (expressing FLNA) cells, but in M2 cells it exhibited marked 
resistance to degradation, compared to A7 cells. Accordingly, internal-
ized EGFR colocalized with the lysosomal marker LAMP-1 in A7 cells but 
not M2 cells [43]. We can hypothesize that in ACC cells, upon IGF2 
binding, IGF1R recruits FLNA, that orchestrates IGF1R internalization 
and subsequent degradative process (Fig. 6). The hypothesis of an 
agonist-dependent mechanism is supported by the observation that 
FLNA silencing induced an effect on IGF1R expression levels only in the 
presence of IGF2 stimulation, but not in basal condition. 
It is worth noting that the IR antibody recognizes both IRA and IRB, 
since no antibody able to discriminate between the two isoforms of IR is 
currently available. Both these isoforms are expressed in ACC [20]. 
While IRA stimulates cancer cell proliferation and survival, IRB is more 
closely linked to metabolic regulation [46]. Since IRA, but not IRB, is a 
high-affinity receptor for IGF2 [47], we can hypothesize that the 
observed IGF2-induced alterations of IR are imputable to IRA. 
We then assessed the impact of the FLNA-induced changes in re-
ceptors expression on downstream intracellular events induced by IGF2. 
In both cell lines and primary cultured ACC cells, we found an 
enhancement of IGF2 effects on cell proliferation and ERK phosphory-
lation after FLNA depletion by siRNA approaches. On the contrary, 
FLNA knockdown did not affect AKT phosphorylation and apoptosis 
induction. This selective enhancement of a specific pathway indicates 
that the observed effects are not simply the result of an increased IGF1R 
expression but are also due to the absence of a negative regulatory ac-
tivity of FLNA on MAPK cascade (Fig. 6). A similar inhibitory effect of 
FLNA was observed in colon carcinoma cells, in which FLNA silencing 
induced an activation of EGFR, AKT and ERK [48], whereas FLNA 
knockdown in mouse lung exerted an opposite effect, impairing AKT and 
ERK activation [49], supporting the specificity of the observed 
mechanism for ACC compared to other tumors. In this regard, it was 
previously demonstrated that FLNA may play a dual role in cancer, also 
depending on its intracellular localization [50]. 
Overall, these results suggest that FLNA in ACC is a specific repressor 
of the IGF2-induced signaling cascade that, through ERK activation, 
promotes cell proliferation. In the absence of FLNA, the increased 
expression of IGF1R associated with the loss of the FLNA regulatory 
activity on ERK pathway, concur to promote IGF2 induced cell growth. 
Since in the absence of FLNA the expression of IR is very low, the 
contribution of IR to the observed cell growth can be considered 
negligible. 
In agreement, a previous study showed that loss of Flna in mouse 
neural progenitor cells resulted in enhanced IGF1R signalling [29]. 
Moreover, a similar FLNA role in impairing the IR ability to activate 
ERK, but not AKT, was demonstrated in melanoma cell line A7 compared 
to M2 [28]. The authors showed that M2 cells exhibited normal IR sig-
nalling, whereas FLNA-expressing A7 cells were unable to elicit 
insulin-dependent Shc tyrosine phosphorylation and ERK activation, 
with no alterations in IR-stimulated phosphorylation of insulin receptor 
substrate-1 or activation of the phosphatidylinositol 3-kinase/AKT 
cascade [28]. Interestingly, in the presence of FLNA, 
insulin-dependent translocation of Shc, SOS1, and ERK to lipid raft was 
reduced. Moreover, the overexpression of a C-terminal fragment of 
FLNA in HepG2 hepatoma cells blocked IR-FLNA interaction and 
potentiated the activity of ERK, but not AKT, suggesting that FLNA in-
teracts with IR to exert an inhibitory tone along the MAPK activation 
pathway [28]. Although further experiments are required to investigate 
the mechanism involved in ERK pathway regulation by FLNA in ACC 
cells, we can hypothesized a similar mechanisms, in which FLNA 
impaired translocation of components of ERK pathway to the membrane 
rafts following IGF2 stimulation. Another hypothesis could be a contri-
bution of FLNA in promoting selective β-arrestins recruitment to IGF1R 
upon IGF2 stimulation, since FLNA is a known β-arrestin2 binding 
partner and β-arrestins 1 and 2 are differentially involved in IGF1R 
desensitization, trafficking and signaling [51]. 
Since FLNA turns down IGF2/IGF1R axis activation, we decided to 
test a possible role of FLNA in determining ACC cells responses to IGF1R 
inhibitors. 
Our results showed that the loss of FLNA in H295R increased cell 
responsiveness to dual IGF1R-IR inhibitor Linsitinb and to the specific 
IGF1R inhibitor NVP-ADW742. In particular, FLNA silencing made cells 
responsive to lower inhibitors concentrations, and at a concentration of 
1 μM the inhibition was significantly greater in silenced than in control 
cells. 
SW13 cells were unresponsive to both inhibitors within the range of 
human maximal plasma concentrations (from 1.7 to 3.1 μM) [23,37], 
however at 5 μM, Linsitinib exerted a significant antiproliferative effect 
only in the absence of FLNA. 
Our data demonstrated that Linsitinib and NVP-ADW742 exerted 
similar effects, supporting a major role for IGF1R. This result is in 
agreement with the FLNA silencing experiments which suggest that the 
contribution of IR to the cell growth can be considered negligible. 
The cell model commonly used to study FLNA functions is the FLNA- 
deficient melanoma cell line M2, together with the FLNA-reconstituted 
cell line A7 [38]. These cell lines expressed IGF1R at comparable 
levels in basal and IGF2 stimulated conditions, suggesting that the ef-
fects of FLNA on the regulation of the agonist-stimulated IGF1R 
expression is specific of ACC cells. Nevertheless, IGF2 was able to induce 
ERK phosphorylation in M2 but not in A7 cells, in agreement with the 
FLNA role as suppressor of IGF1R signaling. In addition, A7 cells were 
completely resistant to inhibitory effects of Linsitinib, whereas it 
strongly reduced ERK activation in M2 cells, in line with what observed 
in ACC cell lines depleted of FLNA. 
In human surgically removed ACC tissue samples, FLNA was 
expressed at variable levels, but mean FLNA expression in ACC was 
significantly lower than in ACA tissues, supporting an increased 
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activation of IGF2 axis in ACC, based on our in vitro results. We found a 
comparable expression of IGF1R in ACC and ACA, as previously shown 
[15], although highly variable in ACC samples. No significant correla-
tion was found between FLNA and IGF1R expression in ACC tissue 
samples, however FLNA/IGF1R ratio was inversely correlated with 
phosphorylated-ERK/total ERK ratio in ACCs, but not in ACAs. This 
suggests that low FLNA levels in ACCs, in the presence of high IGF1R 
expression, enhance IGF2 signal toward ERK. Due to the small size of 
ACC group, no correlation between their clinico-pathological features 
and the expression of FLNA have been made. Admittedly, further studies 
in a large cohort of patients are required to confirm the expression data 
and functional studies, and to evaluate the use of FLNA as a new ACC 
prognostic factor. Due to the small number of primary cultures and 
tissue samples analysed, our conclusions might be applicable only in 
some subgroups of patients. 
Overall, these data support a FLNA role in decreasing both IGF2 
mitogenic effects and the efficacy of IGF1R inhibitors. We can hypoth-
esize that in the absence of FLNA, IGF2/IGF1R pathway represents the 
main trigger for tumor cell growth, and in this condition the inhibition of 
IGF1R can reach a major impact on cell proliferation. The loss of FLNA 
might thus represent a novel predictive biomarker for the identification 
of subpopulation of patients in which IGF1R-targeted therapy can be 
effective. 
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